About

Erik N. Newman, MD, is an allergist and immunologist who cares for patients of all ages. His clinical interests include asthma, food allergy, immunodeficiency, and the full spectrum of allergic conditions such as allergic rhinitis, drug allergy, urticaria, angioedema, atopic dermatitis, anaphylaxis, stinging insect allergy, and eosinophilic disorders. His primary academic focus is medical education. He has served as core faculty at the University of Utah School of Medicine and currently directs Allergy and Immunology education for the pediatric residency. Dr. Newman also co-developed the University of Utah’s Allergy and Immunology Fellowship, where he now serves as Associate Program Director. He attended the University of Washington School of Medicine, completed his pediatric residency at the University of Utah and Primary Children’s Hospital, and trained in allergy and immunology at the University of Colorado and Children’s Hospital Colorado.

Research topics

• Medicine
• Immunology
• Internal medicine
• Pediatrics
• Family medicine
• Dermatology

Selected publications

• Evaluation of Basophil Activation Tests to Diagnose Tolerance to Food Allergens

  Authorea (Authorea) · 2022

  1st authorCorresponding
  • Medicine
  • Family medicine
  • Immunology

  Title: Evaluation of Basophil Activation Tests to Diagnose Tolerance to Food Allergens Erik N. Newman, MDa,b, Patricia Merkel, MSc, Leah Huey, BSc, Maureen Bauer, MDc, Matthew Greenhawt, MD, MBA, MScc, Vijaya Knight MD, PhDcaDepartment of Dermatology, University of Utah School of MedicinebDivision of Allergy & Immunology, Department of Pediatrics, University of Utah School of MedicinecDepartment of Pediatrics, Section of Allergy and Immunology, Children’s Hospital Colorado, University of Colorado School of MedicineSource of Funding: University of Colorado Department of Pediatrics and Children’s Hospital Colorado Research InstituteDisclosure: Matthew Greenhawt is supported by grant #5K08HS024599-02 from the Agency for Healthcare Research and Quality; is an expert panel and coordinating committee member of the NIAID-sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi/Genzyme, Genentech, GlaxoSmith Kline, Merck, Nutricia, Kaleo Pharmaceutical, Nestle, Aquestive, Allergy Therapeutics, AllerGenis, Aravax, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, Aimmune Therapeutics, DBV Technologies, Before Brands, multiple state allergy societies, the American College of Allergy Asthma and Immunology, the European Academy of Allergy and Clinical Immunology; is an associate editor for the Annals of Allergy, Asthma, and Immunology; and is a member of the Joint Taskforce on Allergy PracticeWORD COUNT: 1149Key words: basophil activation test, food allergy, diagnostic testing

  PublisherOA PDFDOI

• Hypogammaglobulinemia after rituximab therapy in children

  Annals of Allergy Asthma & Immunology · 2021 · 7 citations

  1st authorCorresponding
  • Medicine
  • Pediatrics
  • Immunology
  PublisherDOI

• Heterozygous Mutations in NFKB2 Exhibit a Broad Clinical Phenotype

  Journal of Allergy and Clinical Immunology · 2018-02-01

  article1st authorCorresponding
  PublisherDOI

• Post-transplantation Development of Food Allergies

  Current Allergy and Asthma Reports · 2018-01-01 · 15 citations

  review1st authorCorresponding
  PublisherDOI

• An evaluation of [F‐18]‐fluorodeoxy‐<scp>D</scp>‐glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing Sarcoma

  Pediatric Blood & Cancer · 2012-11-28 · 87 citations

  article1st authorCorresponding

  BACKGROUND: Staging investigations following the diagnosis of Ewing sarcoma may include chest computerized tomography (CT), technetium bone scintigraphy (bone scan), [F-18]-fluorodeoxy-D-glucose positron emission tomography (FDG-PET) scan, and bone marrow biopsy and aspiration (BMA/Bx). Each of these staging investigations provides complementary prognostic information, however the optimal combination of staging investigations is not clear. PROCEDURE: We conducted a retrospective study of 91 patients diagnosed with Ewing sarcoma and consecutively treated at our medical facilities between January 1, 2001 and December 31, 2011. We compared the radiologist's interpretations of staging FDG-PET and bone scans. We additionally compared the results of imaging evaluations to bilateral and unilateral BMA/Bx. RESULTS: We found FDG-PET and bone scan to have an examination-based concordance rate of 98% (one discordant case with a positive FDG-PET and negative bone scan). The region-based concordance rate for the imaging modalities was 97% for all cases and 63% for metastatic cases. The ipsilateral concordance rate for BMA/Bx was 98% with BMBx detecting metastases in seven cases and BMA detecting metastases in four cases. The left versus right concordance rates for BMBx and BMA were 98% and 97%, respectively. In all cases where bone marrow metastases were detected by BMA or BMBx, FDG-PET and bone scan detected osseous metastases. CONCLUSIONS: Our study indicates FDG-PET may be sufficient for initial screening for osseous metastases and identified all patients who also have bone marrow metastases. If osseous metastases are detected, a bone scan can detect additional osseous lesions and BMBx may indicate prognostic bone marrow metastases.

  PublisherDOI

Frequent coauthors

• Harry R. Hill

  University of Utah

  6 shared

• Hirokazu Kanegane

  Tokyo Medical and Dental University

  4 shared

• Chaim M. Roifman

  SickKids Foundation

  4 shared

• Douglas S. Hawkins

  University of Washington

  3 shared

• William Rae

  AstraZeneca (United Kingdom)

  3 shared

• C Slade

  Walter and Eliza Hall Institute of Medical Research

  2 shared

• Patricia Merkel

  University of Colorado Denver

  2 shared

• Julie Feusier

  ARUP Laboratories (United States)

  2 shared